Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 574

1.

Current Unmet Needs in Spondyloarthritis.

Poddubnyy D, Sieper J.

Curr Rheumatol Rep. 2019 Jul 13;21(9):43. doi: 10.1007/s11926-019-0844-7. Review.

PMID:
31302784
2.

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.

Sieper J, Landewé R, Magrey M, Anderson JK, Zhong S, Wang X, Lertratanakul A.

RMD Open. 2019 Jun 7;5(1):e000917. doi: 10.1136/rmdopen-2019-000917. eCollection 2019.

3.

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

4.

[Health care and disease burden in persons with axial spondyloarthritis in Germany].

Haibel H, Redeker I, Zink A, Callhoff J, Marschall U, Hoffmann F, Sieper J, Poddubnyy D.

Z Rheumatol. 2019 Jun 6. doi: 10.1007/s00393-019-0650-7. [Epub ahead of print] German.

PMID:
31172266
5.

Peripheral spondyloarthritis: Concept, diagnosis and treatment.

Molto A, Sieper J.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):357-368. doi: 10.1016/j.berh.2019.02.010. Epub 2019 Mar 2. Review.

PMID:
31171308
6.

Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis.

Llop M, Rios Rodriguez V, Redeker I, Sieper J, Haibel H, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2019 May 24;21(1):126. doi: 10.1186/s13075-019-1913-z.

7.

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?

van Lunteren M, van der Heijde D, Sepriano A, Berg IJ, Dougados M, Gossec L, Jacobsson L, Ramonda R, Rudwaleit M, Sieper J, Landewé R, van Gaalen FA.

Rheumatology (Oxford). 2019 Apr 1. pii: kez095. doi: 10.1093/rheumatology/kez095. [Epub ahead of print]

PMID:
30938446
8.

Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.

Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, Poddubnyy D.

Rheumatology (Oxford). 2019 Mar 21. pii: kez090. doi: 10.1093/rheumatology/kez090. [Epub ahead of print]

PMID:
30903141
9.

Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis.

Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, Mansmann U, Rudwaleit M, Poddubnyy D.

Rheumatology (Oxford). 2019 Mar 4. pii: kez025. doi: 10.1093/rheumatology/kez025. [Epub ahead of print]

PMID:
30830164
10.

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.

Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, Nurwakagari P, Weinman J.

RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585. eCollection 2019.

11.

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care.

Poddubnyy D, Callhoff J, Spiller I, Listing J, Braun J, Sieper J, Rudwaleit M.

RMD Open. 2018 Dec 5;4(2):e000825. doi: 10.1136/rmdopen-2018-000825. eCollection 2018.

12.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
13.

Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study.

Greese J, Diekhoff T, Sieper J, Schwenke C, Makowski MR, Poddubnyy D, Hamm B, Hermann KGA.

J Rheumatol. 2019 Apr;46(4):376-383. doi: 10.3899/jrheum.171425. Epub 2019 Jan 15.

PMID:
30647167
14.

Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept.

Rios Rodriguez V, Hermann KG, Weiß A, Listing J, Haibel H, Althoff C, Proft F, Behmer O, Sieper J, Poddubnyy D.

Arthritis Rheumatol. 2019 May;71(5):722-728. doi: 10.1002/art.40786. Epub 2019 Mar 7.

PMID:
30625261
15.

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.

Braun J, Deodhar A, Landewé R, Baraliakos X, Miceli-Richard C, Sieper J, Quebe-Fehling E, Martin R, Porter B, Gandhi KK, van der Heijde D; MEASURE 1 and MEASURE 2 study groups.

RMD Open. 2018 Nov 21;4(2):e000749. doi: 10.1136/rmdopen-2018-000749. eCollection 2018.

16.

Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis.

Riechers E, Baerlecken N, Baraliakos X, Achilles-Mehr Bakhsh K, Aries P, Bannert B, Becker K, Brandt-Jürgens J, Braun J, Ehrenstein B, Euler HH, Fleck M, Hein R, Karberg K, Köhler L, Matthias T, Max R, Melzer A, Meyer-Olson D, Rech J, Rockwitz K, Rudwaleit M, Schmidt RE, Schweikhard E, Sieper J, Stille C, von Hinüber U, Wagener P, Weidemann HF, Zinke S, Witte T.

Arthritis Rheumatol. 2019 May;71(5):729-735. doi: 10.1002/art.40777. Epub 2019 Mar 20.

PMID:
30418704
17.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group.

Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

PMID:
30360964
18.

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D.

Arthritis Rheumatol. 2019 Feb;71(2):258-270. doi: 10.1002/art.40728. Epub 2018 Dec 29.

PMID:
30225992
19.

An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus.

Schulte-Wrede U, Sörensen T, Grün JR, Häupl T, Hirseland H, Steinbrich-Zöllner M, Wu P, Radbruch A, Poddubnyy D, Sieper J, Syrbe U, Grützkau A.

Arthritis Res Ther. 2018 Aug 29;20(1):191. doi: 10.1186/s13075-018-1692-y.

20.

Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study.

Diekhoff T, Greese J, Sieper J, Poddubnyy D, Hamm B, Hermann KA.

Ann Rheum Dis. 2018 Nov;77(11):1585-1589. doi: 10.1136/annrheumdis-2018-213393. Epub 2018 Aug 10.

PMID:
30097454
21.
22.

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK.

Lancet. 2018 Jul 14;392(10142):134-144. doi: 10.1016/S0140-6736(18)31362-X. Epub 2018 Jun 29.

PMID:
29961640
23.

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Baeten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ.

Ann Rheum Dis. 2018 Sep;77(9):1295-1302. doi: 10.1136/annrheumdis-2018-213328. Epub 2018 Jun 26.

24.

Response to 'Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno et al.

Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Ann Rheum Dis. 2019 Jun;78(6):e55. doi: 10.1136/annrheumdis-2018-213620. Epub 2018 May 31. No abstract available.

PMID:
29853451
25.

Age- and Sex-dependent Frequency of Fat Metaplasia and Other Structural Changes of the Sacroiliac Joints in Patients without Axial Spondyloarthritis: A Retrospective, Cross-sectional MRI Study.

Ziegeler K, Eshkal H, Schorr C, Sieper J, Diekhoff T, Makowski MR, Hamm B, Hermann KG.

J Rheumatol. 2018 Jul;45(7):915-921. doi: 10.3899/jrheum.170904. Epub 2018 Apr 15.

PMID:
29657142
26.

Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.

van der Heijde D, Sieper J, Maksymowych WP, Lambert RG, Chen S, Hojnik M, Anderson JK, Pangan AL.

Arthritis Res Ther. 2018 Mar 27;20(1):61. doi: 10.1186/s13075-018-1556-5.

27.

What low back pain is and why we need to pay attention.

Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, Hoy D, Karppinen J, Pransky G, Sieper J, Smeets RJ, Underwood M; Lancet Low Back Pain Series Working Group.

Lancet. 2018 Jun 9;391(10137):2356-2367. doi: 10.1016/S0140-6736(18)30480-X. Epub 2018 Mar 21. Review.

PMID:
29573870
28.

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.

Van den Bosch F, Mease PJ, Sieper J, Baeten DL, Xia Y, Chen S, Pangan AL, Song IH.

RMD Open. 2018 Feb 26;4(1):e000566. doi: 10.1136/rmdopen-2017-000566. eCollection 2018.

29.

Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.

Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Ann Rheum Dis. 2018 Jul;77(7):1017-1024. doi: 10.1136/annrheumdis-2017-212629. Epub 2018 Mar 10.

30.

Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic Research.

Dubreuil M, Sieper J.

Arthritis Rheumatol. 2018 Jul;70(7):981-983. doi: 10.1002/art.40462. Epub 2018 May 7. No abstract available.

31.

Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.

Hebeisen M, Neuenschwander R, Scherer A, Exer P, Weber U, Tamborrini G, Micheroli R, Wildi LM, Zufferey P, Nissen MJ, Villiger PM, Bernhard J, Finckh A, van der Horst-Bruinsma IE, Sieper J, Landewé R, van der Heijde D, Ciurea A; rheumatologists of the Swiss Clinical Quality Management Program.

J Rheumatol. 2018 Apr;45(4):506-512. doi: 10.3899/jrheum.170166. Epub 2018 Feb 15.

PMID:
29449504
32.

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.

RMD Open. 2017 Dec 28;3(2):e000592. doi: 10.1136/rmdopen-2017-000592. eCollection 2017.

33.

Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort.

Poddubnyy D, Listing J, Haibel H, Knüppel S, Rudwaleit M, Sieper J.

Rheumatology (Oxford). 2018 Apr 1;57(4):703-711. doi: 10.1093/rheumatology/kex475.

PMID:
29373733
34.

Disease activity in ankylosing spondylitis: the global therapeutic target.

Wendling D, Prati C, Sieper J.

Ann Rheum Dis. 2018 Aug;77(8):1095-1096. doi: 10.1136/annrheumdis-2017-212363. Epub 2017 Dec 15. No abstract available.

PMID:
29247127
35.

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.

Protopopov M, Sieper J, Haibel H, Listing J, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2017 Oct 24;19(1):240. doi: 10.1186/s13075-017-1453-3.

36.

What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

Poddubnyy D, Sieper J.

Rheumatology (Oxford). 2017 Oct 12. doi: 10.1093/rheumatology/kex361. [Epub ahead of print]

PMID:
29040753
37.

The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.

Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12.

PMID:
28811201
38.

Mechanism of New Bone Formation in Axial Spondyloarthritis.

Poddubnyy D, Sieper J.

Curr Rheumatol Rep. 2017 Sep;19(9):55. doi: 10.1007/s11926-017-0681-5. Review.

PMID:
28752489
39.

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Erratum in: Ann Rheum Dis. 2018 Mar;77(3):472.

40.

Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial.

Hartl A, Sieper J, Syrbe U, Listing J, Hermann KG, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2017 Jun 15;19(1):140. doi: 10.1186/s13075-017-1350-9.

42.

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.

Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B.

Int J Rheum Dis. 2017 May;20(5):589-596. doi: 10.1111/1756-185X.13094. Epub 2017 May 25. Erratum in: Int J Rheum Dis. 2017 Jul;20(7):911.

PMID:
28544533
43.

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.

van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ, Walsh J, Davies O, Bauer L, Hoepken B, Peterson L, Deodhar A.

Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509. doi: 10.1093/rheumatology/kex174.

44.

Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.

Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, van den Bosch F, Wei JC, Pedersen R, Bonin R, Jones H, Marshall L, Logeart I, Vlahos B, Bukowski JF, Maksymowych WP.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1590-1598. doi: 10.1002/acr.23276. Epub 2017 Aug 31.

45.

Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC.

Weiß A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit M.

RMD Open. 2017 Mar 21;3(1):e000366. doi: 10.1136/rmdopen-2016-000366. eCollection 2017.

46.

Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time.

Baraliakos X, Sieper J, Chen S, Pangan AL, Anderson JK.

Rheumatology (Oxford). 2017 Jul 1;56(7):1162-1166. doi: 10.1093/rheumatology/kex081.

47.

Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis.

Heftdal LD, Andersen T, Jæhger D, Woetmann A, Østgård R, Kenngott EE, Syrbe U, Sieper J, Hvid M, Deleuran B, Kragstrup TW.

J Mol Med (Berl). 2017 Jul;95(7):779-787. doi: 10.1007/s00109-017-1528-2. Epub 2017 Apr 2.

PMID:
28365787
48.

Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.

Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH.

J Rheumatol. 2017 May;44(5):599-608. doi: 10.3899/jrheum.160387. Epub 2017 Mar 15.

49.

Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study.

Diekhoff T, Hermann KG, Greese J, Schwenke C, Poddubnyy D, Hamm B, Sieper J.

Ann Rheum Dis. 2017 Sep;76(9):1502-1508. doi: 10.1136/annrheumdis-2016-210640. Epub 2017 Mar 10.

PMID:
28283515
50.

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; Measure 2 Study Group.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7.

Supplemental Content

Loading ...
Support Center